Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Cardiome Pharma Corp. : Cardiome Announces Worldwide Sales And Marketing Of BRINAVESS

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2013 | 09:03pm CEST

Vancouver, Canada, April 25, 2013 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has taken on responsibility for worldwide sales, marketing, and promotion of BRINAVESS™ (vernakalant IV) pursuant to a Transition Agreement signed with Merck, known as MSD outside the United States and Canada.  Under the agreement, worldwide sales and marketing rights will transfer to Cardiome immediately.  Pursuant to this agreement, Cardiome will continue to receive relevant royalties on worldwide sales.  Cardiome will also receive an undisclosed promotional services fee.  Regulatory product rights and product distribution responsibility are expected to transfer to Cardiome on or about July 15, 2013, following which Cardiome will recognize all BRINAVESS™ revenue and Merck will cease paying royalties or any promotional services fee.  Merck will either terminate or transfer Sponsor responsibility for each relevant clinical study to Cardiome by September 15, 2013. 

"Executing this transition agreement with Merck and commencing direct worldwide commercial sales activities in support of BRINAVESS™, ahead of schedule, is a critical milestone in Cardiome's history," stated William Hunter, M.D., President and CEO of Cardiome. "Outreach activities to physicians and caregivers who rely on BRINAVESS™ have resumed in select countries, which will enable us to gain valuable insight and experience in treating patients and help ensure a smooth transition of the product."

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer 
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions.  Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2013 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

For Further Information:
Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Email: [email protected]

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
04/12CARDIOME PHARMA : Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECC..
04/07CARDIOME PHARMA : Announces Amendment to Term Loan Agreement with CRG-Managed Fu..
04/02CARDIOME PHARMA : Highlights Partner SteadyMed's Progress Towards Trevyent NDA R..
03/28CARDIOME PHARMA : Announces Recent Insider Purchases
03/22CARDIOME PHARMA CORP : Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts T..
03/22CARDIOME PHARMA : Health Canada Accepts Cardiome's Xydalba New Drug Submission a..
03/22CARDIOME PHARMA CORP : Blog Exposure - Cipher to Acquire Cardiome’s Canadian Bus..
03/13CARDIOME PHARMA : Reports Fourth Quarter and Full Year 2017 Financial Results
03/13CARDIOME PHARMA CORP : Cardiome Pharma Corp. to Host Earnings Call
03/06CARDIOME PHARMA : to Hold Fourth Quarter and Full Year 2017 Financial Results Co..
More news
News from SeekingAlpha
04/13Key events next week - healthcare 
03/20Midday Gainers / Losers (03/20/2018) 
03/20HEALTHCARE - TOP 5 GAINERS / LOSERS : 15 am (3/20/2018) 
03/20PREMARKET GAINERS AS OF 9 : 05 am (03/20/2018) 
03/20Cardiome to divest Canadian business to Cipher Pharma for C$25.5M 
Financials ( CAD)
Sales 2018 40,3 M
EBIT 2018 -26,9 M
Net income 2018 -27,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 2,53x
Capi. / Sales 2019 1,70x
Capitalization 102 M
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Technical analysis trends CARDIOME PHARMA CORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 8,61  CAD
Spread / Average Target 195%
EPS Revisions
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Justin A. Renz Chief Financial Officer
Richard M. Glickman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED13.09%55 896
BIOGEN-17.44%55 645
GRIFOLS-4.16%17 743